Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, ...

Structure Therapeutics recently reported in Nature Medicine and at the American Diabetes Association’s 86th Scientific Sessions that its oral GLP-1 receptor agonist aleniglipron achieved statistically ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) with bullish sentiments. Deliver ...

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:00 AM EDTCompany ParticipantsRaymond ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...

Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...